Medicare 'Coverage With Evidence' May Rise With FDA Postmarket Emphasis
This article was originally published in The Gray Sheet
Executive Summary
As FDA touts plans to shift clinical data requirements when possible to the postmarket phase, a top CMS official highlights the importance of the Medicare coverage with evidence development policy.